£630m biotech 打開

By IAN KING
Updated: 00:00 BST, 7 November 1999

?

麻薬s group Medeva is の近くに to agreeing a £630 million 引き継ぎ／買収 by Celltech-Chiroscience that would create a £1.3 billion 軍隊 in the UK 生物工学 産業.

The 取引，協定, which is likely to be 現在のd as a 合併 of equals, could be 発表するd as 早期に as tomorrow.

Under the 協定, Medeva 株主s will be 申し込む／申し出d the 同等（の） of about 185p a 株 in cash and Celltech-Chiroscience 株, valuing the company at almost £630 million.

Medeva's 長，指導者 (n)役員／(a)執行力のある 法案 Bogie, who has twice this year walked away from 可能性のある 合併s or 引き継ぎ／買収s, is 推定する／予想するd to take a 重要な 役割 in the 合併するd company.

Bogie broke off 会談 in September with Elan, the Irish 麻薬s group, which is believed to have 申し込む／申し出d between 160p and 170p a 株 for Medeva.

In July, he also walked away from 会談 with Britain's Shire 製薬のs, which had 明らかに 申し込む／申し出d about 190p a 株. Shire has since 合併するd with American group Roberts.

In both 事例／患者s, Bogie is thought to have been 持つ／拘留するing out for 200p a 株, which would have valued Medeva at nearer £700 million.

However, it is thought that some 株主s were unhappy with the 欠如（する） of 進歩 and 勧めるd Bogie 支援する to the 交渉するing （米）棚上げする／（英）提議する.

Some 分析家s have 警告するd recently that without a 引き継ぎ／買収 賞与金 the 株 are 価値（がある） いっそう少なく than 100p.

Medeva 株 have fallen from 330p in 早期に 1997 to Friday's の近くに of just 159p.

Medeva and Celltech-Chiro-science are believed to have discussed the 可能性 of a 合併 at their 勝つ／広く一帯に広がるing 株 prices in June - just before Celltech decided to 合併する with Chiro-science. Since then, Celltech-Chiroscience has quickly 設立するd itself as the most important member of Britain's fledgling 生物工学 産業, where it is by far the biggest company.

It is seen as one of the more exciting plays in the 部門 at the moment because of its 'pipeline' of new 製品s and the prospects for Chirocaine, its anaesthetic, which has already 安全な・保証するd regulatory 是認.

By contrast, Medeva has a 明確に defined 大臣の地位 of 製品s but is seen as having 女性 growth prospects.

Its best known 製品 is methylphenidate, which is used in the 治療 of hyperactive children.

Methylphenidate has recently 苦しむd a 後退 through 落ちるing sales in the ひどく 競争の激しい US market.

But Medeva 誇るs an 設立するd US sales 網状組織, something that Celltech -Chiroscience 欠如（する）s, which is what is thought to have attracted both Shire and Elan to it.